Published in Can Fam Physician on August 01, 1983
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet (2000) 2.90
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol (1993) 2.16
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Immunological and pharmacological monitoring in the clinical use of cyclosporin A. Lancet (1981) 1.77
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
The use of consensus guidelines for management of cytomegalovirus infection in renal transplantation. Kidney Int (2007) 1.57
The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation (1993) 1.55
Cyclosporin prevents diabetes in BB Wistar rats. Lancet (1983) 1.50
Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant (2000) 1.49
Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit (1997) 1.48
Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int (2006) 1.42
What will increase the number of organs for transplantation? Some strategies to consider. CMAJ (1994) 1.39
The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc (1982) 1.38
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem (1990) 1.16
Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med (1983) 1.10
Cyclosporin A: a powerful immunosuppressant. Can Med Assoc J (1982) 1.09
Anti-donor immune responses in prediction of transplant rejection. N Engl J Med (1976) 1.04
The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med (1986) 1.03
Effects of a gold salt on lymphocyte responses. Clin Exp Immunol (1977) 0.99
Small bowel transplantation in the dog using cyclosporine. Transplantation (1983) 0.99
Measles antibodies as related to HL-A types in multiple sclerosis. Neurology (1976) 0.99
Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature (1996) 0.97
HLA antigens in systemic lupus erythematosus: relationship to disease severity, age at onset, and sex. J Rheumatol (1984) 0.97
Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med (1997) 0.96
HLA-typing in multiple sclerosis sibling pairs. Lancet (1982) 0.95
Mechanisms of immunosuppression by cyclosporin. Transplant Proc (1981) 0.92
Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol (1987) 0.92
Regulation of the immune response. X. Antigen-antibody complex inactivation of cells involved in adoptive transfer. J Immunol (1974) 0.90
Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation (1984) 0.89
Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol (1992) 0.89
Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol (1993) 0.89
Liver transplantation: the initial experience of a Canadian centre. Can J Surg (1985) 0.88
Autoimmunity: present concepts. Ann Intern Med (1975) 0.88
Late renal-artery thrombosis after transplantation associated with intraoperative abdominopelvic compression. N Engl J Med (1990) 0.88
Improved renal allograft survival after blood transfusion: a nonspecific, erythrocyte-mediated immunoregulatory process? Lancet (1979) 0.87
Histocompatibility antigens as markers of abnormal iron metabolism in idiopathic hemochromatosis. Can Med Assoc J (1978) 0.87
Organ donors in the eighties: The Ministers Task Force on Kidney Donation. Introduction. Transplant Proc (1985) 0.86
Cyclosporine: action, pharmacokinetics, and effect in the BB rat model. Metabolism (1983) 0.86
The relationship of ischemia-reperfusion injury of transplanted lung and the up-regulation of major histocompatibility complex II on host peripheral lymphocytes. J Thorac Cardiovasc Surg (1998) 0.86
Microcirculatory changes in livers of mice infected with murine hepatitis virus. Evidence from microcorrosion casts and measurements of red cell velocity. Microvasc Res (1988) 0.86
Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion. Ann N Y Acad Sci (1993) 0.85
Percutaneous transluminal dilatation of transplant renal artery stenosis. Postgrad Med J (1981) 0.85
Distribution of DRB1 and DQB1 HLA class II alleles in occupational asthma due to western red cedar. Eur Respir J (2000) 0.84
Cytomegalovirus epididymitis following renal transplantation. J Urol (1991) 0.84
Transplantation in the 80s: a blueprint for success. Transplant Proc (1985) 0.84
Primary acute renal failure ("acute tubular necrosis") in the transplanted kidney: morphology and pathogenesis. Medicine (Baltimore) (1989) 0.83
Lymphocyte-dependent antibody and renal graft rejection. Lancet (1975) 0.83
Humoral and cell-mediated immunity in transfused uraemics. Proc Eur Dial Transplant Assoc (1973) 0.83
Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Diabetes (1991) 0.83
Effect of recovery from ischemic injury on class I and class II MHC antigen expression. Transplantation (1990) 0.82
Experimental and clinical liver transplantation. Transplant Proc (1982) 0.82
Monocyte dependent excited oxygen radical generation in rheumatoid arthritis: inhibition by gold sodium thiomalate. J Rheumatol (1983) 0.82
Clinical and biochemical expression of the genetic abnormality in idiopathic hemochromatosis. Gastroenterology (1980) 0.82
Monoclonal antibodies for radioimmunoassay of cyclosporine: a multicenter comparison of their performance with the Sandoz polyclonal radioimmunoassay kit. Clin Chem (1988) 0.81
An introduction to utility measurement in health care. Infect Control Hosp Epidemiol (1995) 0.81
Initial human pancreas transplantation and attempts to improve pancreatic duct anastomosis. Transplant Proc (1985) 0.81
Cyclosporin for pulmonary sarcoidosis. Lancet (1984) 0.80
The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. Transplant Proc (1998) 0.80
Late acute rejection occurring in liver allograft recipients. Can J Gastroenterol (1996) 0.80
Temporal effect of cyclosporine immunosuppression on T lymphocyte subsets, Ia-reactive cells, and donor-specific immunity in cardiac allograft recipients. Transplant Proc (1984) 0.80
Monitoring of rejection. Transplant Proc (1979) 0.80
Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet (1985) 0.80
Cell-mediated autoimmunity in NZB mice. Clin Exp Immunol (1973) 0.80
Kidney transplantation. Surg Clin North Am (1986) 0.79
Inhibition of the donor-specific immune response by cyclosporin-A following renal transplantation. Transplant Proc (1981) 0.79
The immunocompromised patient. Can Fam Physician (1987) 0.79
Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study. J Autoimmun (1990) 0.79
Fibrous hyperplasia of the gingiva: a side effect of cyclosporin A therapy. Oral Surg Oral Med Oral Pathol (1983) 0.79
Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients. Transplantation (1997) 0.79
Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma. Leuk Lymphoma (2000) 0.79
Lymphocyte subsets in the allograft recipient: correlation of helper to suppressor ratio with clinical events. Transplant Proc (1982) 0.79
Circulating lymphocyte subpopulations in experimental allergic neuritis. J Neuroimmunol (1984) 0.79
Use of cyclosporin a despite renal dysfunction. N Engl J Med (1981) 0.79
Successful paternity of twins following bone marrow transplantation with busulfan, melphalan and cyclophosphamide conditioning. Bone Marrow Transplant (1996) 0.79
Effect of a 21-aminosteroid, U74006F, on lipid peroxidation and glomerulotubular function following experimental renal ischemia. J Surg Res (1994) 0.78
Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol (1994) 0.78
Effects of immunosuppression with cyclosporine in insulin-dependent diabetes mellitus of recent onset: the Canadian open study at 44 months. Transplant Proc (1988) 0.78
The role of inflammatory mediators in the mechanism of the host immune response induced by ischemia-reperfusion injury. Immunol Invest (2000) 0.78